Call for Abstract

9th International conference on Clinical Research and Diagnosis, will be organized around the theme “An established clinical research attributes rigorous clinical trials and good clinical practice ”

Clinical Research and Diagnosis 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Clinical Research and Diagnosis 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Patient-oriented research
  • Track 1-2Epidemiologic and behavioral studies
  • Track 1-3Outcomes research and health services research
  • Track 1-4Ethical Principles of Clinical Research
  • Track 1-5Clinical Trial Process
  • Track 2-1Drug targets
  • Track 2-2Rational drug discovery
  • Track 2-3Computer-aided drug design
  • Track 2-4ligand based and Structure based drug designs
  • Track 3-1New chemical entity development
  • Track 3-2Valuation
  • Track 3-3Success rate
  • Track 3-4Novel initiatives to boost development
  • Track 4-1Human Clinical Trial Phases
  • Track 4-2Participating in a Clinical Trial
  • Track 4-3Funding Clinical Trials
  • Track 4-4Patient Education Resources
  • Track 5-1Clinical trial results in clinical practice
  • Track 5-2Multidisciplinary team approaches to care
  • Track 5-3Personal perspectives in treating a disease
  • Track 5-4Anatomy and physiological studies
  • Track 5-5Studies and case reports on oncology, radiology, immunology, neurophysiology, clinical biochemistry, bioengineering, ageing, allergy, cancer- diagnosis, treatments and therapy
  • Track 5-6Epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy
  • Track 5-7Practical approaches to disease management, pain management and rehabilitation
  • Track 5-8Researches and innovations in cardiology, epidemiology, pathology, parasitology, microbiology, radiotherapy, neurology, pediatrics, nutrition and child care
  • Track 5-9Diabetes Research and Clinical Practice, prevention, technologies and therapy, complications, new treatments
  • Track 5-10Translational science, genetics, immunology, nutrition, psychosocial research
  • Track 6-1Active comparator studies
  • Track 6-2Master protocol
  • Track 6-3Clinical trial protocol
  • Track 6-4Design features
  • Track 6-5Placebo groups
  • Track 6-6Treatment studies (Randomized controlled trial, Adaptive clinical trial, Non-randomized trial)
  • Track 6-7Observational studies (Descriptive, Analytical)
  • Track 7-1Prevention trials
  • Track 7-2Screening trials
  • Track 7-3Diagnostic trials
  • Track 7-4Treatment trials
  • Track 7-5Behavioral trials
  • Track 7-6Quality of life trials
  • Track 8-1TRANSMISSION TO CPMP (COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE)
  • Track 8-2TRANSMISSION TO INTERESTED PARTIES
  • Track 8-3DEADLINE FOR COMMENTS
  • Track 8-4FINAL APPROVAL BY CPMP (COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE)
  • Track 8-5DATE FOR COMING INTO OPERATION
  • Track 9-1Eligibility criteria
  • Track 9-2Patient selection process
  • Track 9-3Ethical considerations
  • Track 9-4Selection of controls
  • Track 11-1Criteria for application
  • Track 11-2Application contents
  • Track 11-3IND types
  • Track 11-4Additional regulations
  • Track 12-1epidemiologic studies of risk factors for the disease
  • Track 12-2in vitro characterization of the chemical and biochemical interactions of new drugs
  • Track 12-3pharmacokinetics, pharmacodynamics and Toxicology
  • Track 12-4reproductive and embryologic effects as a function of dose
  • Track 12-5in vivo drug-drug interactions
  • Track 13-1Clinical trials for Alzheimer’s
  • Track 13-2Trials on pulmonary/respiratory diseases
  • Track 13-3Clinical trials for rare diseases: Challenges and opportunities
  • Track 13-4Clinical trials for diabetes and cardiovascular diseases
  • Track 13-5Clinical trials on Oncology and AIDS
  • Track 14-1clinical outcomes
  • Track 14-2Surrogate outcomes
  • Track 14-3Multiple outcomes
  • Track 15-1Sponsorship in non-commercial clinical trials
  • Track 15-2Regulatory challenges associated with conducting multi-country clinical trials in resource-limited settings
  • Track 15-3Site-Sponsor Relationship in Clinical Studies: Problems and Solutions
  • Track 15-4Site Sustainability Factors
  • Track 15-5How Partnerships Evolve
  • Track 15-6How do Sponsors and CROs Feel About Sites
  • Track 15-7How to make Site-Sponsor Relationship Work Better for Both Sides
  • Track 16-1Database Development
  • Track 16-2Development of Case Report Forms
  • Track 16-3Clinical Research Data Standards
  • Track 16-4Analysis of Study Data
  • Track 16-5Important Considerations
  • Track 16-6Analysis Methods
  • Track 16-7Clinical Study in Project Management